The Zweig Fund, Inc.  

(Public, NYSE:ZF)   Watch this stock  
Find more results for ZF
12.80
-0.04 (-0.31%)
Jul 28 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 12.77 - 12.82
52 week 11.00 - 14.45
Open 12.81
Vol / Avg. 37,283.00/59,929.00
Mkt cap 256.61M
P/E     -
Div/yield 0.36/6.04
EPS     -
Shares 20.28M
Beta 0.96
Inst. own 40%

Key stats and ratios

2010
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets - -
Return on average equity - -
CDP Score - -

Address

100 Munson St
GREENFIELD, MA 01301
United States - Map
+1-800-2722700 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

The Zweig Fund, Inc. (the Fund) is a closed-end, diversified management investment company. The Fund's investment objective is capital appreciation, with income as a secondary objective. The Fund invests in various sectors, such as consumer discretionary, consumer staples, energy, financials, healthcare, industrials, information technology, materials and telecommunication services. Zweig Advisers LLC acts as the advisor for the Fund.

Officers and directors

George R. Aylward CPA Chairman of the Board, President, Chief Executive Officer
Age: 51
Bio & Compensation  - Reuters
W. Patrick Bradley CPA Chief Financial Officer, Vice President, Treasurer
Age: 43
Bio & Compensation  - Reuters
Carlton B. Neel Executive Vice President
Age: 48
Bio & Compensation  - Reuters
David C. Dickerson Senior Vice President
Age: 48
Bio & Compensation  - Reuters
Nancy J. Engberg Chief Compliance Officer
Age: 59
Bio & Compensation  - Reuters
William J. Renahan Vice President, Chief Legal Officer, Secretary
Age: 46
Bio & Compensation  - Reuters
R. Keith Walton Lead Independent Director
Age: 50
Bio & Compensation  - Reuters
James Beeland Rogers Jr. Independent Director
Age: 73
Bio & Compensation  - Reuters
William H. Wright II Independent Director
Age: 55
Bio & Compensation  - Reuters
Brian T. Zino Independent Director
Age: 63
Bio & Compensation  - Reuters